Company: INKT
Filing Date: 2025-12-10
Form Type: S-3/A
Source: 0001193125-25-314252
Chunk: 40

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-12-10
Form: S-3/A
Chunk 40
---
 plans.

S-4

RISK FACTORS

Before purchasing any of the securities you should carefully consider the risk factors relating to MiNK described below and incorporated by reference in this prospectus supplement and the accompanying prospectus from our Annual Report on Form 10-Kfor the year ended December 31, 2024, our Quarterly Reports on Form 10-Qfor the quarters ended March 31, 2025 June 30, 2025 and September 30, 2025, as well as the risks, uncertainties and additional information set forth in our reports on Forms 10-K, 10-Qand 8-Kfiled with the SEC, and in the other documents incorporated by reference into this prospectus and the accompanying prospectus. For a description of these reports and documents, and information about where you can find them, see “Where You Can Find More Information; Incorporation By Reference.” Additional risks not presently known or that we presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business and prospects.

Additional Risks Relating to this Offering and Our Common Stock

We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve.

We currently intend to use the net proceeds of this offering, if any, for working capital and other general corporate purposes which may
include, without limitation, research and development expenditures, preclinical and clinical development and commercialization of our product candidates, the acquisition or in-licensing of products or product
candidates, business or technologies, collaborations, working capital and capital expenditures. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and
timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from clinical trials, as well as any collaborations that we may enter into with
third parties for our product candidates, and any unforeseen cash needs. Because of the number and variability of factors that will determine our use of the proceeds from this offering, their ultimate use may vary substantially from their currently
intended use. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering and could spend the proceeds in ways that do not necessarily improve our operating results or enhance the value of our
common stock. See “Use of Proceeds.”

If you purchase our common stock in this offering, you will incur immediate and substantial dilution in